Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

William George Kaelin, M.D.

TitleProfessor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana Farber Cancer Institute
Medicine-Oncology M 457
44 Binney St
Boston MA 02115
Phone617/632-3975
Fax617/632-4760

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kaelin WG, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013 Mar 28; 153(1):56-69.
    View in: PubMed
  2. Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, Cowley GS, Root DE, Ebert BL, Kaelin WG. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29; 339(6127):1621-5.
    View in: PubMed
  3. Beshiri ML, Holmes KB, Richter WF, Hess S, Islam AB, Yan Q, Plante L, Litovchick L, Gévry N, Lopez-Bigas N, Kaelin WG, Benevolenskaya EV. Coordinated repression of cell cycle genes by KDM5A and E2F4 during differentiation. Proc Natl Acad Sci U S A. 2012 Nov 6; 109(45):18499-504.
    View in: PubMed
  4. Kaelin WG. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science. 2012 Jul 27; 337(6093):421-2.
    View in: PubMed
  5. Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013 Feb; 23(1):18-25.
    View in: PubMed
  6. Querbes W, Bogorad RL, Moslehi J, Wong J, Chan AY, Bulgakova E, Kuchimanchi S, Akinc A, Fitzgerald K, Koteliansky V, Kaelin WG. Treatment of erythropoietin deficiency in mice with systemically administered siRNA. Blood. 2012 Aug 30; 120(9):1916-22.
    View in: PubMed
  7. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H, Kaelin WG. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012 Mar 22; 483(7390):484-8.
    View in: PubMed
  8. Kaelin WG. Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol. 2011; 76:335-45.
    View in: PubMed
  9. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, Depinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, Tabernero J, Gabriel S, Lander ES, Getz G, Meyerson M. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Oct; 43(10):964-8.
    View in: PubMed
  10. Li L, Kaelin WG. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am. 2011 Aug; 25(4):667-86.
    View in: PubMed
  11. Lin W, Cao J, Liu J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Kulkarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG, Yan Q. Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A. 2011 Aug 16; 108(33):13379-86.
    View in: PubMed
  12. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, Kaelin WG. Genetic and Functional Studies Implicate HIF1a as a 14q Kidney Cancer Suppressor Gene. Cancer Discov. 2011 Aug; 1(3):222-35.
    View in: PubMed
  13. Sorrell AD, Lee S, Stolle C, Ellenhorn J, Grix A, Kaelin WG, Weitzel JN. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma. Clin Genet. 2011 Jun; 79(6):539-45.
    View in: PubMed
  14. Wei W, Kaelin WG. Good COP1 or bad COP1? In vivo veritas. J Clin Invest. 2011 Apr; 121(4):1263-5.
    View in: PubMed
  15. Astuti D, Ricketts CJ, Chowdhury R, McDonough MA, Gentle D, Kirby G, Schlisio S, Kenchappa RS, Carter BD, Kaelin WG, Ratcliffe PJ, Schofield CJ, Latif F, Maher ER. Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility. Endocr Relat Cancer. 2011 Feb; 18(1):73-83.
    View in: PubMed
  16. Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, Hu J, Jiang S, Fletcher-Sananikone E, Zhuang L, Chang M, Zheng H, Wang YA, Kwiatkowski DJ, Kaelin WG, Signoretti S, DePinho RA. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell. 2010 Nov 16; 18(5):472-84.
    View in: PubMed
  17. Kaelin WG. New cancer targets emerging from studies of the Von Hippel-Lindau tumor suppressor protein. Ann N Y Acad Sci. 2010 Oct; 1210:1-7.
    View in: PubMed
  18. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaelin WG. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010 Sep 7; 122(10):1004-16.
    View in: PubMed
  19. Inuzuka H, Tseng A, Gao D, Zhai B, Zhang Q, Shaik S, Wan L, Ang XL, Mock C, Yin H, Stommel JM, Gygi S, Lahav G, Asara J, Xiao ZX, Kaelin WG, Harper JW, Wei W. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell. 2010 Aug 9; 18(2):147-59.
    View in: PubMed
  20. Minamishima YA, Kaelin WG. Reactivation of hepatic EPO synthesis in mice after PHD loss. Science. 2010 Jul 23; 329(5990):407.
    View in: PubMed
  21. Rogers LR, LoRusso P, Nadler P, Malik G, Shields A, Kaelin W. Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report. J Neurooncol. 2011 Jan; 101(2):307-10.
    View in: PubMed
  22. Kaelin WG, Thompson CB. Q&A: Cancer: clues from cell metabolism. Nature. 2010 Jun 3; 465(7298):562-4.
    View in: PubMed
  23. Loda M, Kaelin WG. Prostate cancer: beta control your hormones. Cancer Cell. 2010 Apr 13; 17(4):311-2.
    View in: PubMed
  24. Bommi-Reddy A, Kaelin WG. Slaying RAS with a synthetic lethal weapon. Cell Res. 2010 Feb; 20(2):119-21.
    View in: PubMed
  25. Zhang Q, Gu J, Li L, Liu J, Luo B, Cheung HW, Boehm JS, Ni M, Geisen C, Root DE, Polyak K, Brown M, Richardson AL, Hahn WC, Kaelin WG, Bommi-Reddy A. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 6; 16(5):413-24.
    View in: PubMed
  26. Kaelin WG. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 2009; 1(10):99.
    View in: PubMed
  27. Kaelin WG. SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Cancer Cell. 2009 Sep 8; 16(3):180-2.
    View in: PubMed
  28. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009 Nov; 29(21):5729-41.
    View in: PubMed
  29. Kim WY, Perera S, Zhou B, Carretero J, Yeh JJ, Heathcote SA, Jackson AL, Nikolinakos P, Ospina B, Naumov G, Brandstetter KA, Weigman VJ, Zaghlul S, Hayes DN, Padera RF, Heymach JV, Kung AL, Sharpless NE, Kaelin WG, Wong KK. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest. 2009 Aug; 119(8):2160-70.
    View in: PubMed
  30. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 1; 69(11):4674-81.
    View in: PubMed
  31. Kaelin WG. Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. Cancer. 2009 May 15; 115(10 Suppl):2262-72.
    View in: PubMed
  32. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009 May 15; 115(10 Suppl):2247-51.
    View in: PubMed
  33. Kaelin WG. Kidney cancer: now available in a new flavor. Cancer Cell. 2008 Dec 9; 14(6):423-4.
    View in: PubMed
  34. van Oevelen C, Wang J, Asp P, Yan Q, Kaelin WG, Kluger Y, Dynlacht BD. A role for mammalian Sin3 in permanent gene silencing. Mol Cell. 2008 Nov 7; 32(3):359-70.
    View in: PubMed
  35. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, Kaelin WG, Grueneberg DA. Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci U S A. 2008 Oct 28; 105(43):16484-9.
    View in: PubMed
  36. Kaelin WG. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008 Nov; 8(11):865-73.
    View in: PubMed
  37. Young AP, Kaelin WG. Senescence triggered by the loss of the VHL tumor suppressor. Cell Cycle. 2008 Jun 15; 7(12):1709-12.
    View in: PubMed
  38. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008 May 23; 30(4):393-402.
    View in: PubMed
  39. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin WG. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 1; 22(7):884-93.
    View in: PubMed
  40. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008 Mar; 10(3):361-9.
    View in: PubMed
  41. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008 Mar 15; 111(6):3236-44.
    View in: PubMed
  42. Kaelin WG, Sawyers CL, Mihich E. Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. Cancer Res. 2007 Dec 1; 67(23):11102-5.
    View in: PubMed
  43. Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell. 2007 Oct 12; 28(1):15-27.
    View in: PubMed
  44. Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol. 2007 Aug; 27(15):5381-92.
    View in: PubMed
  45. Klose RJ, Yan Q, Tothova Z, Yamane K, Erdjument-Bromage H, Tempst P, Gilliland DG, Zhang Y, Kaelin WG. The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell. 2007 Mar 9; 128(5):889-900.
    View in: PubMed
  46. Kaelin WG. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):680s-684s.
    View in: PubMed
  47. Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 2):667s-670s.
    View in: PubMed
  48. Yan Q, Bartz S, Mao M, Li L, Kaelin WG. The hypoxia-inducible factor 2alpha N-terminal and C-terminal transactivation domains cooperate to promote renal tumorigenesis in vivo. Mol Cell Biol. 2007 Mar; 27(6):2092-102.
    View in: PubMed
  49. Kaelin WG. The von hippel-lindau tumor suppressor protein: an update. Methods Enzymol. 2007; 435:371-83.
    View in: PubMed
  50. Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007; 2:145-73.
    View in: PubMed
  51. Binné UK, Classon MK, Dick FA, Wei W, Rape M, Kaelin WG, Näär AM, Dyson NJ. Retinoblastoma protein and anaphase-promoting complex physically interact and functionally cooperate during cell-cycle exit. Nat Cell Biol. 2007 Feb; 9(2):225-32.
    View in: PubMed
  52. Kim WY, Kaelin WG. Molecular pathways in renal cell carcinoma--rationale for targeted treatment. Semin Oncol. 2006 Oct; 33(5):588-95.
    View in: PubMed
  53. Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, Regan M, Kaelin WG. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. EMBO J. 2006 Oct 4; 25(19):4650-62.
    View in: PubMed
  54. Kaelin WG. Cell biology: divining cancer cell weaknesses. Nature. 2006 May 4; 441(7089):32-4.
    View in: PubMed
  55. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, Kotani H, Manabe T, Zhang GJ, Kondo K, Nosé V, Kaelin WG. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol. 2006 Feb; 168(2):574-84.
    View in: PubMed
  56. Nakamura E, Kaelin WG. Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma. Endocr Pathol. 2006; 17(2):97-106.
    View in: PubMed
  57. Safran M, Kim WY, O'Connell F, Flippin L, Günzler V, Horner JW, Depinho RA, Kaelin WG. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A. 2006 Jan 3; 103(1):105-10.
    View in: PubMed
  58. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005 Sep; 5(9):689-98.
    View in: PubMed
  59. Kaelin WG. The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing. Biochem Biophys Res Commun. 2005 Dec 9; 338(1):627-38.
    View in: PubMed
  60. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG, Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell. 2005 Aug; 8(2):155-67.
    View in: PubMed
  61. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell. 2005 Jul; 8(1):25-33.
    View in: PubMed
  62. Benevolenskaya EV, Murray HL, Branton P, Young RA, Kaelin WG. Binding of pRB to the PHD protein RBP2 promotes cellular differentiation. Mol Cell. 2005 Jun 10; 18(6):623-35.
    View in: PubMed
  63. Kaelin WG. ROS: really involved in oxygen sensing. Cell Metab. 2005 Jun; 1(6):357-8.
    View in: PubMed
  64. Kaelin WG. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing. Cold Spring Harb Symp Quant Biol. 2005; 70:159-66.
    View in: PubMed
  65. Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem. 2005; 74:115-28.
    View in: PubMed
  66. Zhang GJ, Kaelin WG. Bioluminescent imaging of ubiquitin ligase activity: measuring Cdk2 activity in vivo through changes in p27 turnover. Methods Enzymol. 2005; 399:530-49.
    View in: PubMed
  67. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004 Dec 15; 22(24):4991-5004.
    View in: PubMed
  68. Olenyuk BZ, Zhang GJ, Klco JM, Nickols NG, Kaelin WG, Dervan PB. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A. 2004 Nov 30; 101(48):16768-73.
    View in: PubMed
  69. Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, Witters LA, Ellisen LW, Kaelin WG. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004 Dec 1; 18(23):2893-904.
    View in: PubMed
  70. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S.
    View in: PubMed
  71. Kaelin WG. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6290S-5S.
    View in: PubMed
  72. Brugarolas J, Kaelin WG. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell. 2004 Jul; 6(1):7-10.
    View in: PubMed
  73. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG. Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med. 2004 Jun; 10(6):643-8.
    View in: PubMed
  74. Kaufman B, Scharf O, Arbeit J, Ashcroft M, Brown JM, Bruick RK, Chapman JD, Evans SM, Giaccia AJ, Harris AL, Huang E, Johnson R, Kaelin W, Koch CJ, Maxwell P, Mitchell J, Neckers L, Powis G, Rajendran J, Semenza GL, Simons J, Storkebaum E, Welch MJ, Whitelaw M, Melillo G, Ivy SP. Proceedings of the Oxygen Homeostasis/Hypoxia Meeting. Cancer Res. 2004 May 1; 64(9):3350-6.
    View in: PubMed
  75. Mihich E, Kaelin W. Fifteenth annual Pezcoller symposium: molecular in vivo visualization of cancer cells. Cancer Res. 2004 Apr 15; 64(8):2929-33.
    View in: PubMed
  76. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, Ohh M. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol. 2004 Apr; 24(8):3251-61.
    View in: PubMed
  77. Kaelin WG. Gleevec: prototype or outlier? Sci STKE. 2004 Mar 23; 2004(225):pe12.
    View in: PubMed
  78. Wei W, Ayad NG, Wan Y, Zhang GJ, Kirschner MW, Kaelin WG. Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex. Nature. 2004 Mar 11; 428(6979):194-8.
    View in: PubMed
  79. Yang H, Ivan M, Min JH, Kim WY, Kaelin WG. Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. Methods Enzymol. 2004; 381:320-35.
    View in: PubMed
  80. Kondo K, Kim WY, Lechpammer M, Kaelin WG. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 2003 Dec; 1(3):E83.
    View in: PubMed
  81. Kaelin WG. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol. 2003 Nov; 14(11):2703-11.
    View in: PubMed
  82. Safran M, Kim WY, Kung AL, Horner JW, DePinho RA, Kaelin WG. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging. 2003 Oct; 2(4):297-302.
    View in: PubMed
  83. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003 Aug; 4(2):147-58.
    View in: PubMed
  84. George DJ, Kaelin WG. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med. 2003 Jul 31; 349(5):419-21.
    View in: PubMed
  85. Kaelin WG. E2F1 as a target: promoter-driven suicide and small molecule modulators. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S48-54.
    View in: PubMed
  86. Jiang Y, Zhang W, Kondo K, Klco JM, St Martin TB, Dufault MR, Madden SL, Kaelin WG, Nacht M. Gene expression profiling in a renal cell carcinoma cell line: dissecting VHL and hypoxia-dependent pathways. Mol Cancer Res. 2003 Apr; 1(6):453-62.
    View in: PubMed
  87. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell. 2003 Apr; 3(4):403-10.
    View in: PubMed
  88. Safran M, Kaelin WG. HIF hydroxylation and the mammalian oxygen-sensing pathway. J Clin Invest. 2003 Mar; 111(6):779-83.
    View in: PubMed
  89. Kim W, Kaelin WG. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev. 2003 Feb; 13(1):55-60.
    View in: PubMed
  90. Ohh M, Kaelin WG. VHL and kidney cancer. Methods Mol Biol. 2003; 222:167-83.
    View in: PubMed
  91. Serebriiskii IG, Mitina O, Pugacheva EN, Benevolenskaya E, Kotova E, Toby GG, Khazak V, Kaelin WG, Chernoff J, Golemis EA. Detection of peptides, proteins, and drugs that selectively interact with protein targets. Genome Res. 2002 Nov; 12(11):1785-91.
    View in: PubMed
  92. Ivan M, Haberberger T, Gervasi DC, Michelson KS, Günzler V, Kondo K, Yang H, Sorokina I, Conaway RC, Conaway JW, Kaelin WG. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci U S A. 2002 Oct 15; 99(21):13459-64.
    View in: PubMed
  93. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002 Sep; 2(9):673-82.
    View in: PubMed
  94. Aiello LP, George DJ, Cahill MT, Wong JS, Cavallerano J, Hannah AL, Kaelin WG. Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416. Ophthalmology. 2002 Sep; 109(9):1745-51.
    View in: PubMed
  95. Reddy A, Kaelin WG. Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol. 2002 Aug; 2(4):366-73.
    View in: PubMed
  96. Kaelin WG. How oxygen makes its presence felt. Genes Dev. 2002 Jun 15; 16(12):1441-5.
    View in: PubMed
  97. Min JH, Yang H, Ivan M, Gertler F, Kaelin WG, Pavletich NP. Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling. Science. 2002 Jun 7; 296(5574):1886-9.
    View in: PubMed
  98. Seelan RS, Irwin M, van der Stoop P, Qian C, Kaelin WG, Liu W. The human p73 promoter: characterization and identification of functional E2F binding sites. Neoplasia. 2002 May-Jun; 4(3):195-203.
    View in: PubMed
  99. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002 Apr; 1(3):237-46.
    View in: PubMed
  100. Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity. Mol Cell Biol. 2002 Mar; 22(6):1947-60.
    View in: PubMed
  101. Ohh M, Kim WY, Moslehi JJ, Chen Y, Chau V, Read MA, Kaelin WG. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 2002 Feb; 3(2):177-82.
    View in: PubMed
  102. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 2001 Dec 1; 15(23):3104-17.
    View in: PubMed
  103. Yang H, Kaelin WG. Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing. Cell Growth Differ. 2001 Sep; 12(9):447-55.
    View in: PubMed
  104. Kim TY, Kaelin WG. Differential control of transcription by DNA-bound cyclins. Mol Biol Cell. 2001 Jul; 12(7):2207-17.
    View in: PubMed
  105. Irwin MS, Kaelin WG. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 2001 Jul; 12(7):337-49.
    View in: PubMed
  106. Genbacev O, Krtolica A, Kaelin W, Fisher SJ. Human cytotrophoblast expression of the von Hippel-Lindau protein is downregulated during uterine invasion in situ and upregulated by hypoxia in vitro. Dev Biol. 2001 May 15; 233(2):526-36.
    View in: PubMed
  107. Hoffman MA, Ohh M, Yang H, Klco JM, Ivan M, Kaelin WG. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum Mol Genet. 2001 May 1; 10(10):1019-27.
    View in: PubMed
  108. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001 Apr 20; 292(5516):464-8.
    View in: PubMed
  109. Kondo K, Kaelin WG. The von Hippel-Lindau tumor suppressor gene. Exp Cell Res. 2001 Mar 10; 264(1):117-25.
    View in: PubMed
  110. Irwin MS, Kaelin WG. Role of the newer p53 family proteins in malignancy. Apoptosis. 2001 Feb-Apr; 6(1-2):17-29.
    View in: PubMed
  111. Ivan M, Kaelin WG. The von Hippel-Lindau tumor suppressor protein. Curr Opin Genet Dev. 2001 Feb; 11(1):27-34.
    View in: PubMed
  112. Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, Marin MC, Farrell PJ, Kaelin WG, Crook T. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 2000 Dec 15; 60(24):6875-7.
    View in: PubMed
  113. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med. 2000 Dec; 6(12):1335-40.
    View in: PubMed
  114. Miyake S, Sellers WR, Safran M, Li X, Zhao W, Grossman SR, Gan J, DeCaprio JA, Adams PD, Kaelin WG. Cells degrade a novel inhibitor of differentiation with E1A-like properties upon exiting the cell cycle. Mol Cell Biol. 2000 Dec; 20(23):8889-902.
    View in: PubMed
  115. Siegert JL, Rushton JJ, Sellers WR, Kaelin WG, Robbins PD. Cyclin D1 suppresses retinoblastoma protein-mediated inhibition of TAFII250 kinase activity. Oncogene. 2000 Nov 23; 19(50):5703-11.
    View in: PubMed
  116. Lissy NA, Davis PK, Irwin M, Kaelin WG, Dowdy SF. A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature. 2000 Oct 5; 407(6804):642-5.
    View in: PubMed
  117. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 2000 Oct 5; 407(6804):645-8.
    View in: PubMed
  118. O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin WG, DePinho RA. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 2000 Sep 1; 14(17):2185-91.
    View in: PubMed
  119. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000 Jul; 2(7):423-7.
    View in: PubMed
  120. Marin MC, Kaelin WG. p63 and p73: old members of a new family. Biochim Biophys Acta. 2000 May 17; 1470(3):M93-M100.
    View in: PubMed
  121. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000 May; 25(1):47-54.
    View in: PubMed
  122. Kaelin WG. The p53 gene family. Oncogene. 1999 Dec 13; 18(53):7701-5.
    View in: PubMed
  123. Ohh M, Takagi Y, Aso T, Stebbins CE, Pavletich NP, Zbar B, Conaway RC, Conaway JW, Kaelin WG. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest. 1999 Dec; 104(11):1583-91.
    View in: PubMed
  124. Kaelin WG. Taking aim at novel molecular targets in cancer therapy. J Clin Invest. 1999 Dec; 104(11):1495.
    View in: PubMed
  125. Kaelin WG. Choosing anticancer drug targets in the postgenomic era. J Clin Invest. 1999 Dec; 104(11):1503-6.
    View in: PubMed
  126. Kaelin WG. Functions of the retinoblastoma protein. Bioessays. 1999 Nov; 21(11):950-8.
    View in: PubMed
  127. Lai A, Lee JM, Yang WM, DeCaprio JA, Kaelin WG, Seto E, Branton PE. RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins. Mol Cell Biol. 1999 Oct; 19(10):6632-41.
    View in: PubMed
  128. Koochekpour S, Jeffers M, Wang PH, Gong C, Taylor GA, Roessler LM, Stearman R, Vasselli JR, Stetler-Stevenson WG, Kaelin WG, Linehan WM, Klausner RD, Gnarra JR, Vande Woude GF. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999 Sep; 19(9):5902-12.
    View in: PubMed
  129. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Levrero M, Wang JY. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999 Jun 24; 399(6738):806-9.
    View in: PubMed
  130. Ohh M, Kaelin WG. The von Hippel-Lindau tumour suppressor protein: new perspectives. Mol Med Today. 1999 Jun; 5(6):257-63.
    View in: PubMed
  131. Kaelin WG. Cancer. Many vessels, faulty gene. Nature. 1999 May 20; 399(6733):203-4.
    View in: PubMed
  132. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG, Oren M, Chen J, Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol. 1999 May; 19(5):3257-66.
    View in: PubMed
  133. Zbar B, Kaelin W, Maher E, Richard S. Third International Meeting on von Hippel-Lindau disease. Cancer Res. 1999 May 1; 59(9):2251-3.
    View in: PubMed
  134. Kamura T, Koepp DM, Conrad MN, Skowyra D, Moreland RJ, Iliopoulos O, Lane WS, Kaelin WG, Elledge SJ, Conaway RC, Harper JW, Conaway JW. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 1999 Apr 23; 284(5414):657-61.
    View in: PubMed
  135. Stebbins CE, Kaelin WG, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science. 1999 Apr 16; 284(5413):455-61.
    View in: PubMed
  136. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K, Adams PD, Bair KW, Kaelin WG. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13; 96(8):4325-9.
    View in: PubMed
  137. Kaelin WG. The emerging p53 gene family. J Natl Cancer Inst. 1999 Apr 7; 91(7):594-8.
    View in: PubMed
  138. Adams PD, Li X, Sellers WR, Baker KB, Leng X, Harper JW, Taya Y, Kaelin WG. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes. Mol Cell Biol. 1999 Feb; 19(2):1068-80.
    View in: PubMed
  139. Kamura T, Sato S, Haque D, Liu L, Kaelin WG, Conaway RC, Conaway JW. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 1998 Dec 15; 12(24):3872-81.
    View in: PubMed
  140. Adams PD, Kaelin WG. Negative control elements of the cell cycle in human tumors. Curr Opin Cell Biol. 1998 Dec; 10(6):791-7.
    View in: PubMed
  141. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol. 1998 Nov; 18(11):6316-24.
    View in: PubMed
  142. Lieubeau-Teillet B, Rak J, Jothy S, Iliopoulos O, Kaelin W, Kerbel RS. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. Cancer Res. 1998 Nov 1; 58(21):4957-62.
    View in: PubMed
  143. Kaelin WG, Maher ER. The VHL tumour-suppressor gene paradigm. Trends Genet. 1998 Oct; 14(10):423-6.
    View in: PubMed
  144. Iliopoulos O, Ohh M, Kaelin WG. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc Natl Acad Sci U S A. 1998 Sep 29; 95(20):11661-6.
    View in: PubMed
  145. Kaelin WG. Another p53 Doppelgänger? Science. 1998 Jul 3; 281(5373):57-8.
    View in: PubMed
  146. Kaelin WG, Iliopoulos O, Lonergan KM, Ohh M. Functions of the von Hippel-Lindau tumour suppressor protein. J Intern Med. 1998 Jun; 243(6):535-9.
    View in: PubMed
  147. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG, Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun; 1(7):959-68.
    View in: PubMed
  148. Lonergan KM, Iliopoulos O, Ohh M, Kamura T, Conaway RC, Conaway JW, Kaelin WG. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol Cell Biol. 1998 Feb; 18(2):732-41.
    View in: PubMed
  149. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, Lassar AB, Kaelin WG. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev. 1998 Jan 1; 12(1):95-106.
    View in: PubMed
  150. Kaelin WG. Alterations in G1/S cell-cycle control contributing to carcinogenesis. Ann N Y Acad Sci. 1997 Dec 29; 833:29-33.
    View in: PubMed
  151. Maher ER, Kaelin WG. von Hippel-Lindau disease. Medicine (Baltimore). 1997 Nov; 76(6):381-91.
    View in: PubMed
  152. Sellers WR, Kaelin WG. Role of the retinoblastoma protein in the pathogenesis of human cancer. J Clin Oncol. 1997 Nov; 15(11):3301-12.
    View in: PubMed
  153. Parr MJ, Manome Y, Tanaka T, Wen P, Kufe DW, Kaelin WG, Fine HA. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med. 1997 Oct; 3(10):1145-9.
    View in: PubMed
  154. Jost CA, Marin MC, Kaelin WG. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997 Sep 11; 389(6647):191-4.
    View in: PubMed
  155. Iliopoulos O, Kaelin WG. The molecular basis of von Hippel-Lindau disease. Mol Med. 1997 May; 3(5):289-93.
    View in: PubMed
  156. Corless CL, Kibel AS, Iliopoulos O, Kaelin WG. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Hum Pathol. 1997 Apr; 28(4):459-64.
    View in: PubMed
  157. Kaelin WG. Recent insights into the functions of the retinoblastoma susceptibility gene product. Cancer Invest. 1997; 15(3):243-54.
    View in: PubMed
  158. Adams PD, Lopez P, Sellers WR, Kaelin WG. Fluorescence-activated cell sorting of transfected cells. Methods Enzymol. 1997; 283:59-72.
    View in: PubMed
  159. Adams PD, Sellers WR, Sharma SK, Wu AD, Nalin CM, Kaelin WG. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol Cell Biol. 1996 Dec; 16(12):6623-33.
    View in: PubMed
  160. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A. 1996 Oct 1; 93(20):10595-9.
    View in: PubMed
  161. Neuman E, Sellers WR, McNeil JA, Lawrence JB, Kaelin WG. Structure and partial genomic sequence of the human E2F1 gene. Gene. 1996 Sep 16; 173(2):163-9.
    View in: PubMed
  162. Grafi G, Burnett RJ, Helentjaris T, Larkins BA, DeCaprio JA, Sellers WR, Kaelin WG. A maize cDNA encoding a member of the retinoblastoma protein family: involvement in endoreduplication. Proc Natl Acad Sci U S A. 1996 Aug 20; 93(17):8962-7.
    View in: PubMed
  163. Sellers WR, Kaelin WG. RB [corrected] as a modulator of transcription. Biochim Biophys Acta. 1996 Aug 8; 1288(1):M1-5.
    View in: PubMed
  164. Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest. 1996 Aug; 75(2):231-8.
    View in: PubMed
  165. Jost CA, Ginsberg D, Kaelin WG. A conserved region of unknown function participates in the recognition of E2F family members by the adenovirus E4 ORF 6/7 protein. Virology. 1996 Jun 1; 220(1):78-90.
    View in: PubMed
  166. Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, Orkin SH, Greenberg ME. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996 May 17; 85(4):549-61.
    View in: PubMed
  167. Adams PD, Kaelin WG. The cellular effects of E2F overexpression. Curr Top Microbiol Immunol. 1996; 208:79-93.
    View in: PubMed
  168. Sellers WR, Rodgers JW, Kaelin WG. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci U S A. 1995 Dec 5; 92(25):11544-8.
    View in: PubMed
  169. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science. 1995 Sep 8; 269(5229):1444-6.
    View in: PubMed
  170. Iliopoulos O, Kibel A, Gray S, Kaelin WG. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med. 1995 Aug; 1(8):822-6.
    View in: PubMed
  171. Neuman E, Flemington EK, Sellers WR, Kaelin WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol. 1995 Aug; 15(8):4660.
    View in: PubMed
  172. Adams PD, Kaelin WG. Transcriptional control by E2F. Semin Cancer Biol. 1995 Apr; 6(2):99-108.
    View in: PubMed
  173. Qin XQ, Livingston DM, Ewen M, Sellers WR, Arany Z, Kaelin WG. The transcription factor E2F-1 is a downstream target of RB action. Mol Cell Biol. 1995 Feb; 15(2):742-55.
    View in: PubMed
  174. Qin XQ, Livingston DM, Kaelin WG, Adams PD. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci U S A. 1994 Nov 8; 91(23):10918-22.
    View in: PubMed
  175. Neuman E, Flemington EK, Sellers WR, Kaelin WG. Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol. 1994 Oct; 14(10):6607-15.
    View in: PubMed
  176. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin WG, Livingston DM. Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell. 1994 Jul 15; 78(1):161-72.
    View in: PubMed
  177. Li Y, Slansky JE, Myers DJ, Drinkwater NR, Kaelin WG, Farnham PJ. Cloning, chromosomal location, and characterization of mouse E2F1. Mol Cell Biol. 1994 Mar; 14(3):1861-9.
    View in: PubMed
  178. Flemington EK, Speck SH, Kaelin WG. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1993 Aug 1; 90(15):6914-8.
    View in: PubMed
  179. Livingston DM, Kaelin W, Chittenden T, Qin X. Structural and functional contributions to the G1 blocking action of the retinoblastoma protein. (the 1992 Gordon Hamilton Fairley Memorial Lecture). Br J Cancer. 1993 Aug; 68(2):264-8.
    View in: PubMed
  180. Wang CY, Petryniak B, Thompson CB, Kaelin WG, Leiden JM. Regulation of the Ets-related transcription factor Elf-1 by binding to the retinoblastoma protein. Science. 1993 May 28; 260(5112):1330-5.
    View in: PubMed
  181. Slansky JE, Li Y, Kaelin WG, Farnham PJ. A protein synthesis-dependent increase in E2F1 mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol. 1993 Mar; 13(3):1610-8.
    View in: PubMed
  182. Kaelin WG, Krek W, Sellers WR, DeCaprio JA, Ajchenbaum F, Fuchs CS, Chittenden T, Li Y, Farnham PJ, Blanar MA, et al. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties. Cell. 1992 Jul 24; 70(2):351-64.
    View in: PubMed
  183. Qin XQ, Chittenden T, Livingston DM, Kaelin WG. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev. 1992 Jun; 6(6):953-64.
    View in: PubMed
  184. Walling DM, Kaelin WG. Pyomyositis in patients with diabetes mellitus. Rev Infect Dis. 1991 Sep-Oct; 13(5):797-802.
    View in: PubMed
  185. Chittenden T, Livingston DM, Kaelin WG. The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. Cell. 1991 Jun 14; 65(6):1073-82.
    View in: PubMed
  186. Kaelin WG, Pallas DC, DeCaprio JA, Kaye FJ, Livingston DM. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell. 1991 Feb 8; 64(3):521-32.
    View in: PubMed
  187. Chittenden T, Livingston DM, Kaelin WG. RB associates with an E2F-like, sequence-specific DNA-binding protein. Cold Spring Harb Symp Quant Biol. 1991; 56:187-95.
    View in: PubMed
  188. Kaelin WG, Ewen ME, Livingston DM. Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product. Mol Cell Biol. 1990 Jul; 10(7):3761-9.
    View in: PubMed
  189. Kaelin WG, Spivak JL. Systemic lupus erythematosus and myelofibrosis. Am J Med. 1986 Nov; 81(5):935-8.
    View in: PubMed
  190. Petronis JD, LaFrance ND, Kaelin W. Lymphoscintigraphy. Eur J Nucl Med. 1985; 10(11-12):560-2.
    View in: PubMed
  191. Kaelin WG, Shrivastav S, Jirtle RL. Blood flow to primary tumors and lymph node metastases in SMT-2A tumor-bearing rats following intravenous flunarizine. Cancer Res. 1984 Mar; 44(3):896-9.
    View in: PubMed
  192. Shrivastav S, Kaelin WG, Joines WT, Jirtle RL. Microwave hyperthermia and its effect on tumor blood flow in rats. Cancer Res. 1983 Oct; 43(10):4665-9.
    View in: PubMed
  193. Kaelin WG, Shrivastav S, Shand DG, Jirtle RL. Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. Cancer Res. 1982 Oct; 42(10):3944-9.
    View in: PubMed
  194. KAELIN W. [Early diagnosis of cancer with capillary dynamic blood test]. Hippokrates. 1952 Sep 30; 23(18):495-501.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Kaelin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
See all (662) concept(s)
_
Co-Authors
See all (82) people
_
Similar People
See all (60) people
_
Same Department
Search Department
Physical Neighbors
_